Trial Profile
A study of a cell division inhibitor in combination with gemcitabine in women with triple-negative breast cancer
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 20 May 2015
Price :
$35
*
At a glance
- Drugs ESP 01 (Primary)
- Indications Triple negative breast cancer
- Focus Adverse reactions
- 20 May 2015 New trial record
- 13 Apr 2015 Esperas plans to initiate this study in the first quarter of 2016.